Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Toronto

$198,600.00

Microfluidic cultivation of CHO and HEK cells for high throughput antibody production

EF 2024-25

Résumé
Low experimental throughput is a particular challenge in the area of new antibody discovery. Genetic engineering techniques can be employed in a relatively high throughput manner to engineer antibody libraries consisting of tens of thousands of potential antibodies for screening. Yet, the expression and production of those antibodies relies on macroscopic techniques that are resource intensive, i.e. standard 125ml flasks shaking at 200rpm. Up to date, the smallest volume obtainable for CHO and HEK cell cultivation involves 96-well setups with deep wells that accommodate 1ml of culture media and require shaking up to 1000rpm. The overarching goal of the current partnership is to engineer a new high-throughput bioprocess that enables cell cultivation and antibody expression in a foot print of a 384-well plate with minimal infrastructure and energy requirements. Although the ultimate use of select antibodies will be therapeutic, this proposal is in the realm of engineering as it is focused on developing a more efficient, miniaturized, bioprocess for antibody expression and production. Through this project we will establish suspended and perfusable 384-well production of: 1) stably expressing CHO cells for antibody production, and 2) transiently transfected HEK Expi293 cells for antibody screening. The partner organization Amgen has everything that is necessary to further commercialize the developed technology. Upon successful achievement of the project milestones and IP licensing, the technology will be transferred via Radisic laboratory members training the staff at Amgen Canada facility. The expected outcomes include: 1) Elimination of high speed shaking resulting in a significant capital cost and operational savings; 2) Simple operation of 384-well plates eliminating the need for a highly skilled operator and the need for complex equipment; 3) Simple harvesting of the culture media by pipetting robots from the top of the hydrogel eliminating the need for centrifugation. Amgen plans to deploy the developed technology initially in Canada and ultimately around the world.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
601518-2024
Name nom
Radisic, Milica M
Department département
Biomedical Engineering, Institute of (BME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
198600
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Microfluidic cultivation of CHO and HEK cells for high throughput antibody production
Keywords
alginate; antibody production; bioprocess engineering; cell culture; cell proliferation; expression; flow; hydrogel; microfluidics; transfection
Application summary
Low experimental throughput is a particular challenge in the area of new antibody discovery. Genetic engineering techniques can be employed in a relatively high throughput manner to engineer antibody libraries consisting of tens of thousands of potential antibodies for screening. Yet, the expression and production of those antibodies relies on macroscopic techniques that are resource intensive, i.e. standard 125ml flasks shaking at 200rpm. Up to date, the smallest volume obtainable for CHO and HEK cell cultivation involves 96-well setups with deep wells that accommodate 1ml of culture media and require shaking up to 1000rpm. The overarching goal of the current partnership is to engineer a new high-throughput bioprocess that enables cell cultivation and antibody expression in a foot print of a 384-well plate with minimal infrastructure and energy requirements. Although the ultimate use of select antibodies will be therapeutic, this proposal is in the realm of engineering as it is focused on developing a more efficient, miniaturized, bioprocess for antibody expression and production. Through this project we will establish suspended and perfusable 384-well production of: 1) stably expressing CHO cells for antibody production, and 2) transiently transfected HEK Expi293 cells for antibody screening. The partner organization Amgen has everything that is necessary to further commercialize the developed technology. Upon successful achievement of the project milestones and IP licensing, the technology will be transferred via Radisic laboratory members training the staff at Amgen Canada facility. The expected outcomes include: 1) Elimination of high speed shaking resulting in a significant capital cost and operational savings; 2) Simple operation of 384-well plates eliminating the need for a highly skilled operator and the need for complex equipment; 3) Simple harvesting of the culture media by pipetting robots from the top of the hydrogel eliminating the need for centrifugation. Amgen plans to deploy the developed technology initially in Canada and ultimately around the world.